Cargando…
Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study
BACKGROUND/AIMS: PF-00547659 is a monoclonal antibody against human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) that prevents the binding of α4β7(+) lymphocytes to MAdCAM-expressing sites in the gastrointestinal tract with high affinity and selectivity, and is being developed for the treat...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Association for the Study of Intestinal Diseases
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000638/ https://www.ncbi.nlm.nih.gov/pubmed/32013314 http://dx.doi.org/10.5217/ir.2019.00039 |
_version_ | 1783494075644641280 |
---|---|
author | Saruta, Masayuki Park, Dong Il Kim, Young-Ho Yang, Suk-Kyun Jang, Byung-Ik Cheon, Jae Hee Im, Jong Pil Kanai, Takanori Katsuno, Tatsuro Ishiguro, Yoh Nagaoka, Makoto Isogawa, Naoki Li, Yinhua Banerjee, Anindita Ahmad, Alaa Hassan-Zahraee, Mina Clare, Robert Gorelick, Kenneth J. Cataldi, Fabio Watanabe, Mamoru Hibi, Toshifumi |
author_facet | Saruta, Masayuki Park, Dong Il Kim, Young-Ho Yang, Suk-Kyun Jang, Byung-Ik Cheon, Jae Hee Im, Jong Pil Kanai, Takanori Katsuno, Tatsuro Ishiguro, Yoh Nagaoka, Makoto Isogawa, Naoki Li, Yinhua Banerjee, Anindita Ahmad, Alaa Hassan-Zahraee, Mina Clare, Robert Gorelick, Kenneth J. Cataldi, Fabio Watanabe, Mamoru Hibi, Toshifumi |
author_sort | Saruta, Masayuki |
collection | PubMed |
description | BACKGROUND/AIMS: PF-00547659 is a monoclonal antibody against human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) that prevents the binding of α4β7(+) lymphocytes to MAdCAM-expressing sites in the gastrointestinal tract with high affinity and selectivity, and is being developed for the treatment of Crohn’s disease (CD). METHODS: OPERA is a randomized, multicenter, double-blind, placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics of PF-00547659 following subcutaneous administration in subjects with active CD, a history of failure or intolerance to anti-tumor necrosis factor and/or immunosuppressants, high-sensitivity C-reactive protein > 3.0 mg/L, and ulcers on colonoscopy. The primary endpoint was Crohn’s Disease Activity Index-70 response at week 8 or 12. Subpopulation analyses for Asian subjects were performed as some differences are observed in genetics and clinical phenotypes in Asian CD patients compared with Western patients. RESULTS: In this study, 265 CD subjects were randomized, with a subpopulation of 21 subjects (8 Japanese and 13 Korean) defined as the Asian population. In the overall and Asian populations; PF-00547659 was pharmacologically active as evidenced by soluble MAdCAM and circulating β7(+) central memory CD4(+) T-lymphocytes, although no clear evidence of efficacy was observed in any clinical endpoints; pharmacokinetics of PF-00547659 in the Asian subpopulation was generally comparable to the overall population; and the safety profile of PF-00547659 appeared acceptable up to 12 weeks of treatment. CONCLUSIONS: In the overall and Asian populations, efficacy of PF-00547659 could not be demonstrated using any clinical endpoints compared with placebo. Pharmacokinetics and safety of PF-00547659 were generally comparable. Further studies with larger numbers of patients are required to confirm our results. (Trial Registration Number: NCT01276509) |
format | Online Article Text |
id | pubmed-7000638 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Korean Association for the Study of Intestinal Diseases |
record_format | MEDLINE/PubMed |
spelling | pubmed-70006382020-02-12 Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study Saruta, Masayuki Park, Dong Il Kim, Young-Ho Yang, Suk-Kyun Jang, Byung-Ik Cheon, Jae Hee Im, Jong Pil Kanai, Takanori Katsuno, Tatsuro Ishiguro, Yoh Nagaoka, Makoto Isogawa, Naoki Li, Yinhua Banerjee, Anindita Ahmad, Alaa Hassan-Zahraee, Mina Clare, Robert Gorelick, Kenneth J. Cataldi, Fabio Watanabe, Mamoru Hibi, Toshifumi Intest Res Original Article BACKGROUND/AIMS: PF-00547659 is a monoclonal antibody against human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) that prevents the binding of α4β7(+) lymphocytes to MAdCAM-expressing sites in the gastrointestinal tract with high affinity and selectivity, and is being developed for the treatment of Crohn’s disease (CD). METHODS: OPERA is a randomized, multicenter, double-blind, placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics of PF-00547659 following subcutaneous administration in subjects with active CD, a history of failure or intolerance to anti-tumor necrosis factor and/or immunosuppressants, high-sensitivity C-reactive protein > 3.0 mg/L, and ulcers on colonoscopy. The primary endpoint was Crohn’s Disease Activity Index-70 response at week 8 or 12. Subpopulation analyses for Asian subjects were performed as some differences are observed in genetics and clinical phenotypes in Asian CD patients compared with Western patients. RESULTS: In this study, 265 CD subjects were randomized, with a subpopulation of 21 subjects (8 Japanese and 13 Korean) defined as the Asian population. In the overall and Asian populations; PF-00547659 was pharmacologically active as evidenced by soluble MAdCAM and circulating β7(+) central memory CD4(+) T-lymphocytes, although no clear evidence of efficacy was observed in any clinical endpoints; pharmacokinetics of PF-00547659 in the Asian subpopulation was generally comparable to the overall population; and the safety profile of PF-00547659 appeared acceptable up to 12 weeks of treatment. CONCLUSIONS: In the overall and Asian populations, efficacy of PF-00547659 could not be demonstrated using any clinical endpoints compared with placebo. Pharmacokinetics and safety of PF-00547659 were generally comparable. Further studies with larger numbers of patients are required to confirm our results. (Trial Registration Number: NCT01276509) Korean Association for the Study of Intestinal Diseases 2020-01 2020-01-30 /pmc/articles/PMC7000638/ /pubmed/32013314 http://dx.doi.org/10.5217/ir.2019.00039 Text en © Copyright 2020. Korean Association for the Study of Intestinal Diseases. All rights reserved. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Saruta, Masayuki Park, Dong Il Kim, Young-Ho Yang, Suk-Kyun Jang, Byung-Ik Cheon, Jae Hee Im, Jong Pil Kanai, Takanori Katsuno, Tatsuro Ishiguro, Yoh Nagaoka, Makoto Isogawa, Naoki Li, Yinhua Banerjee, Anindita Ahmad, Alaa Hassan-Zahraee, Mina Clare, Robert Gorelick, Kenneth J. Cataldi, Fabio Watanabe, Mamoru Hibi, Toshifumi Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study |
title | Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study |
title_full | Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study |
title_fullStr | Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study |
title_full_unstemmed | Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study |
title_short | Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study |
title_sort | anti-madcam-1 antibody (pf-00547659) for active refractory crohn’s disease in japanese and korean patients: the opera study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000638/ https://www.ncbi.nlm.nih.gov/pubmed/32013314 http://dx.doi.org/10.5217/ir.2019.00039 |
work_keys_str_mv | AT sarutamasayuki antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy AT parkdongil antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy AT kimyoungho antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy AT yangsukkyun antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy AT jangbyungik antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy AT cheonjaehee antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy AT imjongpil antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy AT kanaitakanori antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy AT katsunotatsuro antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy AT ishiguroyoh antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy AT nagaokamakoto antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy AT isogawanaoki antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy AT liyinhua antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy AT banerjeeanindita antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy AT ahmadalaa antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy AT hassanzahraeemina antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy AT clarerobert antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy AT gorelickkennethj antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy AT cataldifabio antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy AT watanabemamoru antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy AT hibitoshifumi antimadcam1antibodypf00547659foractiverefractorycrohnsdiseaseinjapaneseandkoreanpatientstheoperastudy |